In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
News|Articles|February 14, 2025
Supplements and Featured Publications
- Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
- Volume 1
- Issue 1
Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.
Advertisement
Advertisement
Precision medicine strengthened its place in cancer care in the US, with over 65 agents receiving accelerated, regular, or expanded approvals in 2024. But these weren’t the only game-changing indications the regulatory agency greenlit throughout the year—label updates, biosimilar approvals, and new formulations of drugs housed under accelerated, regular, or expanded pathways also changed practice.
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Advertisement
Advertisement